| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4961 | Su11606 | Potent c-MET inhibitor |
|
| DCC4962 | Su11652 | Sunitinib analog, acting as a potential inhibitor for nucleoside diphosphate kinase (NDK) from Leishmania major (LmNDK) |
|
| DCC4963 | Su-200 | Agonist of TRPV1 |
|
| DCC4964 | Su9518 | Novel potent and selective inhibitor of the cellular PDGF receptor kinase and PDGF receptor-induced cell proliferation |
|
| DCC4965 | Subglutinol A | Natural immunosuppressive agent, effectively blocking T cell proliferation and survival while profoundly inhibiting pro-inflammatory IFNγ and IL-17 production by fully differentiated effector Th1 and Th17 cells, also acting as an estrogen receptor antagon |
|
| DCC4966 | Suc-leu-leu-val-tyr-amc | Fluorescent substrate which can be hydrolyzed by the proteasome to release free AMC and the fluorescence of which is proportional to the proteasome activity |
|
| DCC4967 | Sucnr1-in-20 Featured | SUCNR1-IN-2 (Statement 35) is a succinate/succinate receptor 1 inhibitor for the study of neurodegenerative diseases such as neuroinflammation. |
|
| DCC4968 | Suku-33 | Novel potent inhibitor of osteoclastogenesis, suppressing both equilibrative nucleoside transporters and concentrative nucleoside transporters |
|
| DCC4969 | Sul-121 Hydrochloride | Novel inhibitor of airway inflammation and hyperresponsiveness in experimental models of chronic obstructive pulmonary disease (COPD) |
|
| DCC4970 | Sulfacetamide | Antibacterial, inhibiting bacterial folic acid synthesis by competing with para amino benzoic acid |
|
| DCC4971 | Sulfazecin | β-Lactam antibiotic against multi-drug resistant pathogens |
|
| DCC4972 | Sulfonyl Quinoxaline 1 | Novel inhibitor of RhoG-hepcidin uptake |
|
| DCC4973 | Sulfosuccinimidyl Oleate Sodium | Neuroprotective agent, alleviating stroke-induced neuroinflammation |
|
| DCC4974 | Suloctidil Hydrochloride | Peripheral vasodilator |
|
| DCC4975 | Sulukast | Novel, potent, selective, and competitive antagonist of LTD4 and LTE4 |
|
| DCC4976 | Sumanirole | D2 selective dopamine agonist, showing anxiolytic and anti-parkinsonian activities |
|
| DCC4977 | Sun13837 | Novel fibroblast growth factor receptor modulator for treating neurodegenerative diseases |
|
| DCC4978 | Sun-c5174 | 5-HT2 antagonist |
|
| DCC4979 | Supradamal | Potent Inhibitor of Plasmodium FK506 Binding Protein 35 (FKBD35), also act as a HIV inhibitor |
|
| DCC4980 | suvanine | Antagonist of the mammalian bile acid sensor farnesoid-X-receptor (FXR) |
|
| DCC4981 | Sv-293 | Selective D2 dopamine receptor antagonist |
|
| DCC4982 | Sv-iii-130s | D2 dopamine receptor partial agonist in adenylyl cyclase inhibition assay and antagonist in the GIRK and phospho ERK1/2 assays |
|
| DCC4983 | Sw208108 | Novel clickable tumor-specific irreversible inhibitor of stearoyl CoA desaturase (SCD) |
|
| DCC4984 | Swainsonine | Natural potent alpha-mannosidase inhibitor, exhibiting antimetastatic, antiproliferative, and immunomodulatory activities |
|
| DCC4985 | swertisin | Potent differentiating agent |
|
| DCC4986 | S-y048 | Novel selective OXE receptor antagonist |
|
| DCC4987 | Sy-5609 | Novel highly potent and selective CDK7 inhibitor, demonstrating broad anti-tumor activity in vivo |
|
| DCC4988 | Syk-524 | Novel universal opioid receptor agonist |
|
| DCC4989 | Syk-in-ii | Novel inhibitor of the Syk kinase (spleen tyrosine kinase) |
|
| DCC4990 | Syn-1 Peptide | Novel potent and specific inhibitor of syncytin-mediated cell fusion, completely blocking cell fusion at 1.6 μg/ml |
|
